Anna Windle

Anna Windle is the Director of Clinical Development, Medical and Regulatory Affairs at Novo Nordisk in the USA. She has been instrumental in the company's efforts to innovate in obesity treatment, particularly in the development of an oral version of the weight-loss medication Wegovy. Windle's insights emphasize the growing demand for individualized treatment plans that accommodate patient preferences, marking a significant shift in the approach to obesity management.